This project has been flagged by a community member as inappropriate due to reason below.*


Slingshot members are conducting a survey! The topic is:

Quarterly Survey: Diabetes GLP-1 Treatments and Mounjaro tirzepatide April 2023

Ticker(s): LLY, NVO, AZN

Who's being surveyed?

The survey includes 20 Endocrinologists.

Survey Questions

How many patients with Type 2 Diabetes do you have under your care?


Are you familiar with Mounjaro (tirzepatide) data to date?


How many of your patients are currently on a GLP-1 treatment?


How many of your patients are eligible for Mounjaro (tirzepatide)?


How many of your patients are on the following GLP-1 treatments today?

  • Mounjaro (tirzepatide):
  • Semaglutide (Ozempic):
  • Liraglutide (Victoza, Saxenda):
  • Dulaglutide (Trulicity):
  • Exenatide extended release (Bydureon bcise):
  • Exenatide (Byetta):
  • Other:


How many patients have started Mounjaro (tirzepatide) in the past 90 days?


How many patients have discontinued Mounjaro (tirzepatide) in the past 90 days?


How many patients do you expect to use Mounjaro (tirzepatide) at the following time points (cumulative)?

  • 90 days/3 months:
  • 1 year:
  • 3 years:


How would you rate Mounjaro (tirzepatide) on the following (where 1 is low and 5 is high)?

  • Safety
  • Efficacy
  • Payor Access


Please elaborate on your view of Mounjaro (tirzepatide). Please be specific.


Do the side effects of Mounjaro (tirzepatide) limit your prescribing rate?


Which side effects limit your prescribing of Mounjaro (tirzepatide)?


What changes, if any, have you noticed with payor reimbursement and insurance for diabetes and weight loss treatments?


What is the most exciting new area of development in your specialty?

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.